| Ms Pearletta Emone Lamey, LPN | |
|
93 Broad St Fl 2, Middletown, CT 06457-3236 | |
| (860) 478-0244 | |
| Not Available |
| Full Name | Ms Pearletta Emone Lamey |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 93 Broad St Fl 2, Middletown, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609452861 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 40428 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Pearletta Emone Lamey, LPN 93 Broad St Fl 2, Middletown, CT 06457-3236 Ph: (860) 478-0244 | Ms Pearletta Emone Lamey, LPN 93 Broad St Fl 2, Middletown, CT 06457-3236 Ph: (860) 478-0244 |
News Archive
Ben-Gurion University of the Negev and Soroka University Medical Center researchers in Beer-Sheva, Israel are developing a cell culture system that for the first time can change testicular stem cells into sperm-like cells that may enable future fertility for boys with prepubertal cancer.
Sonomax Hearing Healthcare Inc. is pleased to announce that it has signed a five year license agreement with Hearing Coach Africa (Pty). The agreement for V3 hearing protectors specifies quarterly commitments over five years, totaling a minimum of $1,000,000. The agreement is renewable for an additional 5 years if all contractual conditions and minimum quarterly commitments are met.
Lung cancer is the leading cause of cancer mortality in the United States, with a five-year survival rate of just 17 percent. Smoking causes approximately 85 percent of all lung cancer cases, only 15 percent of which are diagnosed at an early stage. Most efforts to obtain early diagnosis have been unsuccessful, largely due to the highly aggressive nature of the disease.
MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.
The benefits of weight loss surgery, along with a treatment plan that includes exercise and dietary changes, are well documented. In addition to a significant decrease in body mass, many patients find their risk factors for heart disease are drastically lowered and blood sugar regulation is improved for those with Type 2 diabetes.
› Verified 4 days ago